HCC
Hepatocellular carcinoma — systemic and locoregional
DefinitionClick to collapse
Hepatocellular carcinoma (HCC) is a primary malignancy arising from hepatocytes, the main parenchymal cells of the liver. It is the most common type of primary liver cancer. The tumor typically develops in the setting of chronic liver disease and cirrhosis, though it can also occur in non-cirrhotic livers, particularly in patients with chronic hepatitis B virus (HBV) infection. Histologically, HCC can present as three gross morphologic types: nodular, massive, and diffuse. The nodular type is the most common and is often associated with cirrhosis, characterized by well-circumscribed nodules. The massive type usually occurs in a non-cirrhotic liver, occupying a large area with or without satellite nodules. The less common diffuse type is characterized by diffuse hepatic involvement with numerous small, indistinct tumor nodules throughout the liver. HCC is radiologically characterized by arterial hypervascularity and contrast 'washout' on portal venous phases, reflecting its predominant blood supply from the hepatic artery, unlike the surrounding liver parenchyma which receives dual blood supply. The disease can remain asymptomatic for much of its natural history; symptoms of more advanced disease include jaundice, anorexia, weight loss, malaise, and upper abdominal pain. Paraneoplastic syndromes, though rare, can occur. Diagnosis is established through characteristic imaging features on multiphasic contrast-enhanced CT or MRI in high-risk patients, often without the need for biopsy. The management and prognosis of HCC are heavily influenced by the degree of underlying liver dysfunction, typically assessed using the Child-Turcotte-Pugh (CTP) score, and the extent of tumor burden.
EpidemiologyClick to collapse
Hepatocellular carcinoma is a major global health burden. In 2025, it was estimated that 42,240 people in the United States would be diagnosed with liver cancer and intrahepatic bile duct cancer, with approximately 30,090 deaths anticipated. Incidence and mortality rates for liver and intrahepatic bile duct cancers have shown recent stabilization in men but have been increasing in women by approximately 2% annually. The incidence of HCC is highest in individuals of American Indian/Alaska Native descent, and forecast analyses predict that HCC rates will be highest in Black individuals and Hispanic individuals over the next 15 years. Increasing incidence rates are predicted for those born between 1950 and 1959, linked to high rates of hepatitis C viral infection in this cohort. Globally, hepatitis B virus (HBV) infection remains the leading cause of HCC incidence and mortality. Approximately 1.5 million people in the United States are chronically infected with HBV. The annual incidence rate of HCC among patients with hepatitis C virus (HCV) with Child-Turcotte-Pugh (CTP) Class A or B cirrhosis is estimated to be ≥1%. While the majority of HCC cases occur in the setting of cirrhosis from various etiologies, certain populations, particularly those with HBV infection, can develop HCC even in the absence of cirrhosis. The disease typically affects individuals in the 5th to 6th decade of life, with a male predominance. The rising incidence in some regions is also attributed to increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), which are expected to become leading underlying etiologies for HCC.
SubtypesClick to collapse
Steatohepatitic HCC
A histologic subtype that morphologically resembles steatohepatitis, often associated with underlying metabolic dysfunction-associated steatotic liver disease (MASLD).
Clear cell HCC
Characterized by hepatocytes with clear cytoplasm due to glycogen or lipid accumulation.
Macrotrabecular HCC
A variant characterized by thickened trabeculae (>6-10 cells thick) of hepatocytes.
Scirrhous HCC
Characterized by a prominent desmoplastic stromal reaction, often with a central scar.
Chromophobe HCC
A subtype with pale, eosinophilic cytoplasm and prominent cell membranes, resembling chromophobe renal cell carcinoma.
Fibrolamellar HCC (FLHCC)
A distinct variant characterized by large oncocytic hepatocytes separated by dense lamellar fibrosis. It is identified by a unique molecular marker, the DNAJB1-PRKACA chimeric transcript, which accurately identifies FLHCC in 79% to 100% of patients. Patients tend to be younger and have a generally better prognosis than those with conventional HCC, though recurrences after resection are common.
Neutrophil-rich HCC
A subtype with a prominent inflammatory infiltrate composed predominantly of neutrophils.
Lymphocyte-rich HCC
A subtype with a prominent lymphocytic infiltrate, potentially indicating an immune response.
Combined HCC-Cholangiocarcinoma (cHCC-CCA)
A rare primary liver tumor containing histologic features of both HCC and intrahepatic cholangiocarcinoma (iCCA). It may present as separate foci of both histologies or as a biphenotypic tumor with co-expression of immunohistochemical markers for both lineages. Multigene panel testing suggests a higher prevalence of genomic alterations more commonly associated with HCC (e.g., TP53, TERT promoter mutations) than CCA.
Molecular PathogenesisClick to collapse
Hepatocellular carcinoma is associated with a complex landscape of genomic alterations. The development of HCC is a multistep process often arising from chronic liver inflammation and cirrhosis, leading to genomic instability and clonal expansion. Key oncogenic signaling pathways implicated in HCC include the Wnt/β-catenin, PI3K/AKT/mTOR, RAS/MAPK, MET, and insulin-like growth factor (IGF) pathways. Mutations in the TP53 tumor suppressor gene and in the promoter region of the telomerase reverse transcriptase (TERT) gene are common events in HCC pathogenesis. While these molecular alterations are recognized, the source text does not provide specific mutation frequencies for these genes in HCC. The molecular pathogenesis is distinct from other primary liver cancers, such as intrahepatic cholangiocarcinoma, which harbors different predominant genomic alterations. For example, the fibrolamellar variant of HCC is characterized by a specific recurrent fusion transcript, DNAJB1-PRKACA, which is a defining molecular feature of this subtype. The source text notes that tumor multigene panel testing (MGPT) is not routinely indicated for HCC but should be considered on a case-by-case basis, particularly for patients with advanced disease, atypical histology, or to identify potential targetable alterations in the rare setting of NTRK fusions or RET fusions. The role of immune-related biomarkers such as microsatellite instability (MSI), mismatch repair (MMR) status, tumor mutational burden (TMB), and PD-L1 expression is not established for patient selection in HCC, as immune checkpoint inhibitors have shown clinical benefit without requiring these selections.
Risk FactorsClick to collapse
Cirrhosis
Any etiology of cirrhosis is a major risk factor. An estimated 60% to 80% of persons with HCC have underlying cirrhosis, possibly approaching 90% in the United States.
Chronic Hepatitis B Virus (HBV) Infection
HBV is the leading global cause of HCC. The annual incidence is estimated to be 0.5% in carriers without cirrhosis and 2.5% in those with known cirrhosis. Additional risk factors in HBV carriers without cirrhosis include high HBV DNA levels, HBeAg positivity, family history of HCC, male sex from endemic countries >40 years, female sex from endemic countries >50 years, and being from Africa at an earlier age.
Chronic Hepatitis C Virus (HCV) Infection
HCV is a major cause of HCC, particularly in the United States and Japan. The annual incidence of HCC among patients with HCV and CTP Class A/B cirrhosis is estimated to be ≥1%. Direct-acting antivirals (DAAs) improve sustained virologic response, which may eventually decrease HCC incidence.
Alcohol-Associated Cirrhosis
Alcohol-related liver disease and MASLD are major contributors to the rise in primary liver disease in the United States. Synergistic interaction with viral hepatitis exists.
Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Metabolic Syndrome
Metabolic disorders (obesity, diabetes, impaired glucose metabolism, MASLD) are associated with increased HCC risk. MASH is anticipated to replace hepatitis as the most common underlying cause of HCC. Screening for HCC in patients with MASLD and advanced liver fibrosis or cirrhosis is recommended.
Other Chronic Liver Diseases
Includes Wilson's disease, primary sclerosing cholangitis, drug-induced liver disease, chronic right-sided heart failure, autoimmune hepatitis, primary biliary cholangitis, hereditary hemochromatosis, porphyria cutanea tarda, alpha-1 antitrypsin deficiency, and Budd-Chiari syndrome. Cirrhosis from these conditions is generally a prerequisite for HCC development.
Hepatitis D Virus (HDV) Co-infection
Patients with HDV infection in addition to HBV have a greater risk of developing HCC compared to those with HBV infection alone.
Male Sex
HCC has a male predominance. Specific risk factors for HBV carriers without cirrhosis differ by gender and geographic origin.
Geographic Region / Ethnicity
HCC rates are highest in American Indian/Alaska Native, Black, and Hispanic individuals. Incidence varies by geographic region, correlating with the prevalence of hepatitis B and C.
Clinical FeaturesClick to collapse
Typical Presentation
Hepatocellular carcinoma (HCC) is frequently diagnosed in the setting of chronic liver disease or cirrhosis, which itself may be asymptomatic. When symptoms occur, they are often nonspecific and related to advanced disease or hepatic decompensation. Classic presentation includes an elevated serum alpha-fetoprotein (AFP) level discovered during surveillance of a high-risk patient, or the identification of a liver nodule on imaging performed for other reasons. Patients may present with right upper quadrant pain, a palpable mass, weight loss, anorexia, malaise, or jaundice. Physical signs can include hepatomegaly, ascites, or features of chronic liver disease such as spider angiomata or palmar erythema. Paraneoplastic syndromes, although rare, can occur and include hypercholesterolemia, erythrocytosis, hypercalcemia, and hypoglycemia. The diagnosis of combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is challenging, as it may present similarly to HCC but can also be associated with elevated CA 19-9.
Symptoms
Right upper quadrant pain
Nonspecific pain or discomfort in the area of the liver.
Weight loss
Unintentional loss of body weight.
Anorexia
Loss of appetite.
Jaundice
Yellowing of the skin and sclera, indicating impaired bilirubin metabolism.
Signs
Hepatomegaly
Enlarged liver palpable on examination.
Ascites
Accumulation of fluid in the peritoneal cavity.
Palpable mass
A mass felt in the right upper quadrant.
Red FlagsClick to collapse
New or rising serum alpha-fetoprotein (AFP) level in a patient with chronic liver disease.
Solid liver nodule ≥10 mm identified on ultrasound during surveillance.
Imaging features suggestive of malignancy (arterial phase hyperenhancement with washout on venous/delayed phase) in a high-risk patient.
Unexplained deterioration in liver function tests in a patient with known cirrhosis.
Symptoms of advanced disease: significant weight loss, persistent right upper quadrant pain, jaundice.
InvestigationsClick to collapse
Diagnostic
Multiphasic abdominal CT or MRI with contrast
Primary modality for non-invasive diagnosis and staging. Recommended after a positive screening test or if a lesion is identified incidentally. Essential for assessing tumor characteristics, vascular invasion, and extrahepatic disease.
Ultrasound (US)
Recommended as the primary screening tool every 6 months for high-risk patients. Limited for characterization but useful for initial detection.
Contrast-enhanced ultrasound (CEUS)
Considered a problem-solving tool at centers with expertise for characterization of indeterminate nodules. Not suitable for whole-liver assessment, surveillance, or staging.
Core needle biopsy
Indicated when imaging does not meet diagnostic criteria for HCC (LI-RADS 5), or in patients not at high risk for HCC (e.g., no cirrhosis, no CHB). Also considered for suspected cHCC-CCA or to confirm metastatic disease. Should be considered before ablation and after multidisciplinary review.
Staging
Chest CT
Routine evaluation for extrahepatic metastases, as lungs are a common site of spread.
Abdomen/Pelvis CT or MRI with contrast
Essential for local staging to assess number, size, and location of hepatic lesions, vascular invasion, lymph node involvement, and other intra-abdominal metastases.
Bone scan
Selective use for patients with skeletal symptoms or when bone metastases are suspected.
Biomarkers
Alpha-fetoprotein (AFP)
A serum biomarker used in conjunction with imaging for diagnosis, surveillance, and monitoring treatment response. An elevated AFP in the context of a characteristic liver mass has a high positive predictive value for HCC.
Des-gamma-carboxy prothrombin (DCP/PIVKA-II) and Lens culinaris agglutinin-reactive AFP (AFP-L3)
Other serum biomarkers being studied. May be used as complementary assays to AFP for screening and diagnosis.
Multigene panel testing (MGPT)/Molecular profiling
There is no established indication for routine molecular profiling in HCC. However, it may be considered on a case-by-case basis for patients with atypical histology, cHCC-CCA histology, unusual clinical presentations, or for clinical trial enrollment.
StagingClick to collapse
AJCC Cancer Staging Manual, 8th Edition (2017)
T Categories
| Stage | Description |
|---|---|
| TX | Primary tumor cannot be assessed. |
| T0 | No evidence of primary tumor. |
| T1a | Solitary tumor ≤2 cm. |
| T1b | Solitary tumor >2 cm without vascular invasion. |
| T2 | Solitary tumor >2 cm with vascular invasion, or multiple tumors, none >5 cm. |
| T3 | Multiple tumors, at least one of which is >5 cm. |
| T4 | Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein, or tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. |
N Categories
| Stage | Description |
|---|---|
| NX | Regional lymph nodes cannot be assessed. |
| N0 | No regional lymph node metastasis. |
| N1 | Regional lymph node metastasis. |
M Categories
| Stage | Description |
|---|---|
| M0 | No distant metastasis. |
| M1 | Distant metastasis. |
Stage Groupings
| Group | Criteria | Clinical Meaning | Five Yr Survival | Treatment Intent |
|---|---|---|---|---|
| Stage IA | T1a N0 M0 | Very early stage. Solitary tumor ≤2 cm, no vascular invasion, no node metastasis, no distant metastasis. | None | Curative (resection, ablation, transplant). |
| Stage IB | T1b N0 M0 | Early stage. Solitary tumor >2 cm without vascular invasion, no node metastasis, no distant metastasis. | None | Curative (resection, ablation, transplant). |
| Stage II | T2 N0 M0 | Intermediate stage. Either a solitary tumor >2 cm with vascular invasion, or multiple tumors none >5 cm, no node metastasis, no distant metastasis. | None | Curative (resection, transplant) or locoregional therapy depending on liver function and tumor location. |
| Stage IIIA | T3 N0 M0 | Advanced stage. Multiple tumors, at least one >5 cm, no node metastasis, no distant metastasis. | None | Locoregional therapy (e.g., TACE), systemic therapy, or clinical trial. |
| Stage IIIB | T4 N0 M0 | Advanced stage. Tumor(s) involve major vascular structures or directly invade adjacent organs, no node metastasis, no distant metastasis. | None | Systemic therapy or clinical trial. Locoregional therapy may be considered in selected cases. |
| Stage IVA | Any T N1 M0 | Advanced stage. Any primary tumor with regional lymph node metastasis, no distant metastasis. | None | Systemic therapy or clinical trial. |
| Stage IVB | Any T Any N M1 | Metastatic stage. Any primary tumor, any nodal status, with distant metastasis. | None | Systemic therapy, best supportive care, or clinical trial. |
Staging Pearls
- The AJCC staging system provides information primarily on pathologic characteristics of resected specimens. For clinical staging, the Barcelona Clinic Liver Cancer (BCLC) system is often used, which incorporates tumor burden, liver function (CTP score), and patient performance status to guide treatment decisions.
- The presence of vascular invasion is a key prognostic factor and is incorporated into the T category (T1b vs. T2, T2 vs. T3/T4). Major vascular invasion (T4) includes invasion of a main branch of the portal or hepatic vein.
- For patients with cirrhosis, the background liver disease stage (e.g., Ishak fibrosis score F0-F6) is a critical component of pathology reporting and influences prognosis and treatment eligibility.
- The BCLC system, while not an anatomic staging system, is widely used to stratify patients into treatment groups (Very Early/Early, Intermediate, Advanced, Terminal).
Management PrinciplesClick to collapse
The management of hepatocellular carcinoma (HCC) requires a comprehensive, multimodal approach due to the complexity of treating both the malignancy and the underlying chronic liver disease/cirrhosis. The fundamental philosophy is to integrate curative-intent therapies (surgical resection, liver transplantation, and ablation) whenever feasible, while employing locoregional and systemic therapies for unresectable or metastatic disease. A multidisciplinary team (MDT) is essential for individualized treatment planning [HCC-3, HCC-4, HCC-5, HCC-6]. Treatment decisions are heavily influenced by tumor burden (extent, number, size, location, vascular invasion), liver function (Child-Pugh class, portal hypertension), patient performance status, and comorbidities [HCC-3]. The goals of care range from curative intent for early-stage disease to life-prolonging and palliative intent for advanced disease. Participation in clinical trials is encouraged for all stages [HCC-1, HCC-6].
Curative
Patients with potentially resectable or transplantable HCC by tumor burden, and operable by performance status or comorbidity (HCC-4).
Liver resection (preferred if criteria met) and/or liver transplantation (preferred if transplant criteria met). For small, properly located tumors, ablation is considered a preferred curative-intent locoregional therapy in well-selected patients during multidisciplinary review. Bridging or downstaging locoregional therapies may be indicated for transplant candidates [HCC-4].
Life-prolonging/Locoregional control
Patients with liver-confined, unresectable HCC who are deemed ineligible for transplant (HCC-5).
Locoregional therapies are the primary approach. Options include ablation (preferred), arterially directed therapies (e.g., TACE, TAE, radioembolization), and radiation therapy (RT). Systemic therapy is an option and should be considered for progression on or after locoregional therapy. Clinical trials are also an option [HCC-5].
Systemic/Palliative
Patients with extrahepatic/metastatic disease, or liver-confined disease ineligible for resection, transplant, or locoregional therapy (HCC-6).
Systemic therapy is a mainstay. Clinical trials, best supportive care, and RT (for symptom control or selected sites) are also key options. Locoregional therapy may be reconsidered in select cases after multidisciplinary review [HCC-6].
All patients with HCC should be evaluated by a multidisciplinary team (MDT). For HCC diagnosis and staging, this includes hepatologists, diagnostic and interventional radiologists, surgeons, medical oncologists, radiation oncologists, and pathologists with HCC expertise [HCC-3]. Multidisciplinary review is strongly recommended for treatment planning in all disease stages, including for patients being considered for surgery, locoregional therapy, or systemic therapy [HCC-4, HCC-5, HCC-6, HCC-G]. The MDT approach is associated with improved outcomes, including higher rates of treatment and curative therapies [MS-7].
Performance status (PS) is a critical determinant of treatment eligibility and intent. Patients must be medically fit for major surgery [HCC-F]. Resection and transplantation are indicated for patients with preserved performance status [HCC-4]. Locoregional therapies require evaluation of liver function and performance status. For systemic therapies, most pivotal trials were conducted in patients with ECOG PS 0-1; use in patients with poorer performance status requires caution and individualized decision-making, particularly in the context of underlying liver dysfunction [HCC-I, HCC-E].
Management PathwaysClick to collapse
Branching: Tumor burden resectability, Transplant criteria eligibility (UNOS), Performance status and comorbidities, Liver function (CTP class), Presence of portal hypertension
Branching: Tumor burden, Liver function (CTP class, portal hypertension), Performance status, Access to locoregional therapies, Prior locoregional therapy response
Branching: Presence of extrahepatic disease, Performance status, Liver function (CTP class), Prior therapy (e.g., checkpoint inhibitor use), Biomarker status (MSI-H, NTRK, RET)
Branching: Resectability, Tumor stage (localized vs. advanced), Dominant histology on biopsy, Molecular profile
Pretreatment EvaluationClick to collapse
Clinical Presentation and Workup: HCC Confirmed
Principles of Imaging
SurgeryClick to collapse
Hepatic resection and liver transplantation are potentially curative treatment options for patients with early-stage HCC who meet specific criteria. They are the preferred treatments for patients who meet resection and/or transplant criteria [HCC-4, MS-41].
Patients must be medically fit for a major operation and evaluated by an MDT [HCC-F].
All patients should be evaluated for possible transplant candidacy [HCC-F].
Resection requires adequate liver function (generally CTP A, no portal hypertension), solitary mass without major vascular invasion, and adequate future liver remnant (≥20% without cirrhosis, ≥30-40% with CTP A cirrhosis) [HCC-F].
Transplantation follows UNOS criteria (single tumor ≥2 cm ≤5 cm, or 2-3 tumors ≥1 cm ≤3 cm; AFP ≤1000 ng/mL; no macrovascular invasion; no extrahepatic disease) or expanded/downstaged criteria [HCC-4, HCC-F].
Minimally invasive approaches by experienced surgeons are safe and effective [MS-14].
Procedures
Partial Hepatectomy
Potentially resectable HCC in patients with CTP A liver function (or highly selected CTP B without portal hypertension), solitary mass without major vascular invasion, and adequate future liver remnant [HCC-F].
Liver Transplantation
Patients meeting UNOS criteria (as above) or downstaged to within criteria. Treats both the tumor and underlying cirrhosis. Preferred for patients with CTP B or C cirrhosis who are not surgical candidates [HCC-4, HCC-F].
Radiation TherapyClick to collapse
RT is a treatment option for patients with unresectable HCC, or for those who are medically inoperable due to comorbidity. It can be used for locoregional control or palliation [HCC-6, HCC-H]. SBRT can be considered as an alternative to ablation/embolization or when these therapies have failed or are contraindicated [HCC-H].
Principles
- Image-guided RT (IGRT) is strongly recommended when using RT, IMRT, and SBRT to improve accuracy and reduce toxicity [HCC-H].
- Tumors may be amenable to RT (3D-CRT, IMRT, or SBRT) [HCC-H].
- The majority of safety and efficacy data are from patients with CTP A liver disease, with growing experience in CTP B7; safety for CTP B8 or CTP C is not established [HCC-H].
- Proton beam therapy may be appropriate in specific situations due to reduced dose to normal tissues [HCC-H].
- Palliative RT is appropriate for symptom control from metastatic lesions (bone, brain) or extensive liver tumor burden in patients with CTP A or B cirrhosis [HCC-H].
Dose Frameworks
| Name | Total Dose | Dose Per Fraction | Fractions | Schedule | Indication |
|---|---|---|---|---|---|
| Stereotactic Body Radiation Therapy (SBRT) | 27.5–60 Gy | Delivered in 3–5 fractions | 3–5 | Hypofractionated | Preferred for patients with 1 to 5 tumors, assuming sufficient uninvolved liver and liver tolerance. Considered as alternative to ablation/embolization or after failure/contraindication of those therapies [HCC-H]. |
| Hypofractionation | 37.5–72 Gy | N/A | 10–15 | Hypofractionated | Acceptable option for intrahepatic tumors [HCC-H]. |
| Conventional Fractionation | 50–66 Gy | N/A | 25–33 | Conventional | Historical or specific clinical scenarios not detailed further [HCC-H]. |
| Palliative Radiation Therapy | 8 Gy | 8 Gy | 1 | Single fraction | For palliation of pain from extensive burden of cancer in the liver [HCC-H]. |
Approaches
| Name | Dose Fractionation | Concurrent Chemotherapy | Indication | Key Trial | Toxicities |
|---|---|---|---|---|---|
| SBRT | Typically 3–5 fractions, total dose 27.5–60 Gy (BED10 >72 Gy preferred if constraints met) [HCC-H]. | Not routinely specified for HCC SBRT in this guideline. | Patients with unresectable HCC, not candidates for ablation/embolization or after failure/contraindication. Can be used for 1-5 tumors with sufficient liver reserve [HCC-H]. | Randomized evidence supports its usefulness (e.g., NRG/RTOG 1112 phase 3 trial) [HCC-H]. | Risk of radiation-induced liver disease (RILD), especially with compromised liver function. Requires strict adherence to dose constraints [HCC-H]. |
| Proton Beam Therapy | Hypofractionated; specific regimen not detailed but cited in references. | Not specified. | May be appropriate in specific situations to reduce dose to adjacent normal tissues [HCC-H]. | Randomized clinical trials comparing to TACE or RFA cited [HCC-H]. | Associated with reduction of dose to adjacent normal tissues compared to photon therapy [HCC-H]. |
| Palliative RT | 8 Gy in 1 fraction for liver pain; other schedules for bone/brain metastases not detailed. | Not specified. | Symptom control and/or prevention of complications from metastatic HCC lesions (bone, brain) or extensive liver tumor burden [HCC-H]. | CCTG HE1 trial cited for palliative RT vs. best supportive care [HCC-H]. | Depends on site treated; generally low for single-fraction liver palliation. |
Systemic TherapyClick to collapse
Systemic therapy is indicated for patients with advanced/metastatic HCC (HCC-6) or for progression on/after locoregional therapy (HCC-5). Treatment selection is based on Child-Pugh class, performance status, prior therapy, and biomarker status. Most pivotal trials were in CTP A patients; use in CTP B requires caution and extrapolation [HCC-I, HCC-E].
Key Regimens
Treatment Response AssessmentClick to collapse
Title
Response Assessment and Surveillance Post-Treatment
Timing
For locoregional therapy: Early imaging per local protocol can be considered. For systemic therapy: Periodic assessment with cross-sectional imaging of sites at risk (chest, multiphasic abdomen, pelvis). For all post-curative intent therapy: Surveillance imaging and AFP every 3-6 months for 2 years, then every 6 months, continuing for at least 5 years [HCC-4, HCC-5, MS-42].
Response Logic
-
For locoregional therapies, response is typically assessed by the extent to which contrast uptake on dynamic CT/MRI is diminished (mRECIST criteria are more suitable than RECIST for HCC) [MS-21].
-
For systemic therapies, response is assessed by standard criteria (e.g., RECIST 1.1). On-treatment AFP changes can be a reliable predictor of tumor response, time to progression, and survival [HCC-I, MS-36].
-
After initial assessment, if disease progresses or is non-responding, the multidisciplinary team should reconsider all options: resection, transplant, alternative locoregional therapy, or subsequent-line systemic therapy [HCC-5, HCC-6].
Imaging Recommendations
-
Multiphasic, high-quality, cross-sectional imaging (CT or MRI) is the preferred method for surveillance and response assessment because of its reliability in assessing arterial vascularity [MS-42].
-
Multiphasic abdomen MRI or multiphase CT scans for liver assessment, CT chest, and CT/MRI pelvis [HCC-4, HCC-5].
-
Surveillance and AFP should continue for at least 5 years; thereafter screening is dependent on HCC risk factors [HCC-4, HCC-5].
Biopsy Or Salvage Logic
-
If imaging is not consistent or to confirm diagnosis, consider core needle biopsy (HCC-B).
-
For patients with extrahepatic/metastatic disease, biopsy should be considered and is preferred to confirm histology before initiating systemic therapy, as noninvasive criteria are less validated in advanced stages [HCC-6, HCC-B].
-
In patients with advanced cHCC-CCA, a repeat biopsy at tumor progression may be warranted to reassess dominant histology, especially if there are discordant areas of response and progression [HCC-C].
-
If a growing mass has a negative biopsy, it does not rule out HCC; continued monitoring and multidisciplinary review are recommended [MS-9].
SurveillanceClick to collapse
Clinical Follow Up Schedule
- Every 3-6 months for 2 years after curative therapy, then every 6 months thereafter.
- For patients on systemic therapy for advanced disease, assess response every 2-3 cycles (approximately every 6-9 weeks) using imaging and AFP.
- Include history, physical exam, and assessment of liver function and performance status at each visit.
Imaging Strategy
- Multiphasic contrast-enhanced CT or MRI of the abdomen and pelvis is preferred for surveillance post-treatment.
- CT chest to assess for lung metastases.
- Use consistent modality and protocol for comparability.
- Consider alternative modality if clinical suspicion discordant with imaging findings.
Laboratory Monitoring
- Serum alpha-fetoprotein (AFP) every 3-6 months post-curative therapy.
- Liver function tests (bilirubin, AST, ALT, ALP, INR) regularly.
- Complete blood count (monitor for portal hypertension-related cytopenias).
- Assessment of viral hepatitis status and viral load (for those with HBV/HCV).
Supportive Follow Up
- Nutritional status assessment and support.
- Screen for depression and anxiety.
- Manage comorbidities (diabetes, cardiovascular disease).
- Bone density screening if on long-term corticosteroids or with risk factors.
ComplicationsClick to collapse
Disease-Related
| Complication | Management |
|---|---|
| Hepatic decompensation (ascites, encephalopathy, variceal bleeding) | Manage portal hypertension (beta-blockers, endoscopic ligation, TIPS), diuretics, lactulose, protein restriction. Refer to hepatologist for transplant evaluation if appropriate. |
| Portal vein tumor thrombosis | May be considered for locoregional therapy (TACE, TARE) in highly selected patients with segmental/lobar invasion. Systemic therapy is primary treatment. |
| Hepatocellular rupture (rare) | Emergency embolization or surgery; stabilize then treat underlying HCC. |
Supportive CareClick to collapse
Supportive care is integral throughout the management of HCC to manage symptoms, treatment toxicities, and underlying liver disease. A multidisciplinary approach including hepatology, palliative care, and nutrition is essential.
Nutritional assessment and intervention are critical due to frequent malnutrition and sarcopenia. Protein intake should not be restricted unless encephalopathy is present. Patients should be evaluated by a dietitian.
Follow ASCO/NCCN antiemetic guidelines based on emetogenic potential of regimen. Prophylaxis for highly emetogenic chemotherapy (e.g., cisplatin-based).
Consider G-CSF prophylaxis for regimens with >20% febrile neutropenia risk. Monitor closely.
Risk assessment using Khorana score. HCC is a moderate to high risk cancer. Prophylaxis with LMWH or DOACs may be considered, balancing bleeding risk (especially with esophageal varices).
Pain assessment using validated tools. Stepwise analgesia (WHO ladder). Avoid hepatotoxic drugs. Consider palliative radiation for painful bone metastases or liver burden.
Screen for distress using NCCN Distress Thermometer. Provide resources for coping, financial toxicity, and advanced care planning.
Evaluation prior to anti-angiogenic therapy to minimize osteonecrosis risk.
PrognosisClick to collapse
Hepatocellular carcinoma (HCC) is associated with a poor prognosis, with many patients diagnosed at an advanced stage. The 5-year survival rate for all stages combined remains low. However, prognosis varies significantly by stage at diagnosis and underlying liver function. The presence of cirrhosis, vascular invasion, and extrahepatic metastases are key adverse prognostic factors. Survival is heavily influenced by the stage at diagnosis, liver functional reserve, and performance status.
By Stage
| Stage | Five Yr Survival | Context |
|---|---|---|
| Early (BCLC 0/A or AJCC Stage I) | Resection: >50% (selected patients ~70%); Transplant (within Milan criteria): 85% at 4 years; Ablation (RFA for <3cm): >50% at 5 years. | Includes very early (single ≤2cm) and early stage (single or ≤3 nodules each ≤3cm) with preserved liver function and good performance status. Curative-intent therapies are options. |
| Intermediate (BCLC B or AJCC Stage II) | TACE: 1- and 3-year survival rates approximately 57% and 26% in one trial. | Multinodular disease without macrovascular invasion or extrahepatic spread, with preserved liver function. Largely treated with arterially directed therapies. |
| Advanced (BCLC C or AJCC Stage III/IV) | Systemic therapy: Median OS ranges from ~11 to 23 months depending on regimen. Sorafenib: median OS 10.7 months. Atezolizumab+Bevacizumab: median OS 19.2 months. | Includes portal vein invasion and/or extrahepatic spread, with preserved liver function but impaired performance status. Systemic therapy is mainstay. |
| Terminal (BCLC D) | Median OS generally <3 months with best supportive care. | End-stage liver function and/or very poor performance status. Management focuses on palliation. |
Prognostic Factors
- Tumor stage (size, number, vascular invasion, extrahepatic disease)
- Liver function (Child-Pugh class, MELD score, portal hypertension)
- Performance status (ECOG)
- Serum alpha-fetoprotein (AFP) level
- Response to therapy
- Underlying etiology and severity of cirrhosis
- Tumor biology and differentiation
Follow UpClick to collapse
Post Curative Treatment
After curative-intent therapy (resection, transplantation, ablation), surveillance is recommended to detect recurrence or new primary tumors. Surveillance includes multiphasic cross-sectional imaging (CT or MRI) and serum AFP every 3-6 months for 2 years, then every 6 months. Surveillance should continue for at least 5 years; thereafter, screening depends on ongoing HCC risk factors.
Surveillance Rationale
Earlier detection of recurrence may allow for repeat curative-intent therapy or eligibility for clinical trials. Recurrence patterns include intrahepatic recurrence (from metachronous new primary or intrahepatic metastasis) and extrahepatic metastases.
Late Effects Screening
- Screening for liver decompensation (ascites, encephalopathy)
- Monitoring for osteoporosis and fractures (related to cirrhosis, corticosteroid use)
- Surveillance for secondary malignancies
- Cardiovascular risk assessment (especially with anti-angiogenic therapy)
Recurrence Patterns
Recurrence after resection is common (>70% at 5 years). Patterns include early recurrence (<2 years) often from intrahepatic metastasis (associated with microvascular invasion) and late recurrence (>2 years) often from de novo multicentric carcinogenesis in the cirrhotic liver.
Key TrialsClick to collapse
| Acronym | Full Name | Year | N | Intervention | Comparator | Population | Primary Endpoint | Key Result | Secondary Outcomes | Practice Change | Journal |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IMbrave150 | Atezolizumab plus bevacizumab versus sorafenib in unresectable hepatocellular carcinoma | 2020 | 501 | Atezolizumab + Bevacizumab | Sorafenib | Unresectable HCC, CTP A, no prior systemic therapy | Overall Survival (OS) and Progression-Free Survival (PFS) | Median OS: 19.2 vs. 13.4 months (HR, 0.66; descriptive P < .001). Median PFS: 6.9 vs. 4.3 months (HR, 0.65; descriptive P < .001). ORR: 27.3% vs. 11.9%. | Duration of response >6 months: 87.6% vs. 59.1%. Grade 3/4 treatment-related adverse events: 43% vs. 46%. | Established atezolizumab+bevacizumab as a preferred first-line systemic therapy option. | New England Journal of Medicine |
| HIMALAYA | Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma | 2022 | 1171 | Tremelimumab + Durvalumab | Sorafenib | Unresectable HCC, CTP A, no prior systemic therapy | Overall Survival (OS) | Median OS: 16.4 vs. 13.8 months (HR, 0.78; P = .0035). 5-year OS rate: 19.6% vs. 9.4%. | No significant PFS difference. Serious treatment-related adverse events: 17.5% vs. 9.9%. | Established tremelimumab+durvalumab as a preferred first-line systemic therapy option. | NEJM Evidence |
| CheckMate 9DW | Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma | 2025 | 668 | Nivolumab + Ipilimumab | Lenvatinib or Sorafenib | Unresectable HCC, CTP A/B, no prior systemic therapy | Overall Survival (OS) | Median OS: 23.7 vs. 20.6 months (HR, 0.79; P = .018). ORR: 36% vs. 13% (P < .0001). | Median DOR: 30.4 vs. 12.9 months. Grade 3-4 treatment-related adverse events: 41% vs. 42%. | Moved ipilimumab+nivolumab to category 1 preferred first-line therapy. Noted higher risk of early death and immune-related adverse events requiring steroids. | The Lancet |
| REFLECT | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma | 2018 | 954 | Lenvatinib | Sorafenib | Unresectable HCC, CTP A, no prior systemic therapy | Non-inferiority in Overall Survival (OS) | Median OS: 13.6 vs. 12.3 months (HR, 0.92; 95% CI, 0.79-1.06). Non-inferiority met. | ORR: 24.1% vs. 9.2%. Median PFS: 7.4 vs. 3.7 months. | Established lenvatinib as a first-line option comparable to sorafenib. | The Lancet |
| SHARP | Sorafenib in advanced hepatocellular carcinoma | 2008 | 602 | Sorafenib | Placebo | Advanced HCC (not eligible for or progression after locoregional therapy), CTP A | Overall Survival (OS) | Median OS: 10.7 vs. 7.9 months (HR, 0.69; P < .001). | Time to radiologic progression: 5.5 vs. 2.8 months. | First systemic therapy to demonstrate survival benefit in advanced HCC. | New England Journal of Medicine |
| CELESTIAL | Cabozantinib in patients with advanced hepatocellular carcinoma | 2018 | 707 | Cabozantinib | Placebo | Advanced HCC, progressed on or after sorafenib, CTP A | Overall Survival (OS) | Median OS: 10.2 vs. 8.0 months (HR, 0.76; P = .005). Median PFS: 5.2 vs. 1.9 months (HR, 0.44; P < .001). | ORR: 4% vs. 0.4%. | Established cabozantinib as a subsequent-line therapy after sorafenib. | New England Journal of Medicine |
| RESORCE | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment | 2017 | 573 | Regorafenib | Placebo | Advanced HCC, progressed on sorafenib, CTP A | Overall Survival (OS) | Median OS: 10.6 vs. 7.8 months (HR, 0.63; P < .001). Median PFS: 3.1 vs. 1.5 months (HR, 0.46; P < .001). | Disease control rate: 65% vs. 36%. | First FDA-approved therapy after sorafenib progression. | The Lancet |
| RASER | Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma | 2022 | 70 | Radiation segmentectomy (Y-90) | N/A (single-arm) | Unresectable very early to early stage HCC, not amenable to RFA | Primary technical effectiveness (complete response) | Complete response rate: 87%. | 3-year OS rate: 94.7%. 3-year PFS rate: 78.4%. | Supports Y-90 radiation segmentectomy as a potential curative therapy for small HCC. | The Lancet Gastroenterology & Hepatology |
| NRG/RTOG 1112 | Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma | 2025 | 176 | SBRT followed by sorafenib | Sorafenib alone | Locally advanced HCC, no prior systemic therapy | Overall Survival (OS) | Median OS: 15.8 vs. 12.3 months (HR, 0.77; P = .06; HR adjusted for stratification factors: 0.72; P = .03). | Median PFS: 9.2 vs. 5.5 months (HR, 0.55; P < .001). | Provides randomized evidence supporting SBRT in locally advanced HCC, though primary endpoint not strictly met. | JAMA Oncology |
| IMbrave050 | Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma | 2023 | 810 | Adjuvant Atezolizumab + Bevacizumab | Active surveillance | Resected or ablated high-risk HCC, CTP A | Recurrence-Free Survival (RFS) | RFS: HR, 0.72 (P = .012) at primary analysis. Updated analysis showed benefit not sustained. | Grade 3-4 treatment-related adverse events: 41% in treatment group. | Initial positive result led to exploration of adjuvant IO, but updated analysis tempered enthusiasm; not included as standard adjuvant option in NCCN. | The Lancet |
Clinical PearlsClick to collapse
- Pearl 1: 1. HCC prognosis is determined by both tumor stage and underlying liver function (Child-Pugh class).
- Pearl 2: 2. Multidisciplinary team evaluation is essential for optimal management at all stages.
- Pearl 3: 3. Curative-intent therapies (resection, transplant, ablation) are limited to early-stage HCC with preserved liver function.
- Pearl 4: 4. Atezolizumab plus bevacizumab and tremelimumab plus durvalumab are category 1 preferred first-line systemic therapies.
- Pearl 5: 5. Alpha-fetoprotein (AFP) is used for surveillance, prognosis, and monitoring response to therapy but is not diagnostic alone.
- Pearl 6: 6. Transplant criteria (UNOS) are based on tumor size, number, and AFP level, not histology, due to high specificity of imaging in cirrhotic patients.
- Pearl 7: 7. Bridge and downstaging therapies are critical for patients awaiting transplant to reduce dropout risk.
- Pearl 8: 8. Systemic therapy in Child-Pugh B cirrhosis is not well-established; use with caution and extrapolate from CTP A data.
Special SituationsClick to collapse
Fibrolamellar HCC
Combined HCC-Cholangiocarcinoma (cHCC-CCA)
HCC with Child-Pugh B Cirrhosis
HCC with Main Portal Vein Thrombosis
HCC on Liver Transplant Waitlist
Recurrent HCC After Curative Therapy
Guidelines ResourcesClick to collapse
NCCN Clinical Practice Guidelines in Oncology: Hepatocellular Carcinoma
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
AJCC Cancer Staging Manual, 8th Edition
Organ Procurement and Transplantation Network Policies
External beam radiation therapy for primary liver cancers: An ASTRO Clinical Practice Guideline
Protective FactorsClick to collapse
- Hepatitis B vaccination (in children and young adults, reduces future risk)
- Successful antiviral therapy for chronic hepatitis B and C (reduces risk of HCC development)